Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SABCS 2021 | Treatment algorithm for TNBC

Bora Lim • 9 Dec 2021

SABCS 2021

Breast Cancer Antibodies Sacituzumab govitecan

Bora Lim, MD, Baylor College of Medicine, Houston, TX, talks on triple-negative breast cancer (TNBC), touching on the development of treatment algorithms for patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

HIF-2α as an alternate therapeutic target in ER+ breast cancer

HIF-2α as an alternate therapeutic target in ER+ breast cancer

Bora Lim • 12 Dec 2024

Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC

Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC

Bora Lim • 12 Dec 2024

LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer

LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer

Bora Lim • 12 Dec 2024

Highlights at SABCS 2021 for basic science and early-phase clinical trials

Highlights at SABCS 2021 for basic science and early-phase clinical trials

Bora Lim • 9 Dec 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?

How will SARMs fit into the current breast cancer treatment paradigm?

Rafael Grochot • 2 Jul 2026

Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer

Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer

Rafael Grochot • 2 Jul 2026

$HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?$

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?

Sanjoy Chatterjee • 17 May 2026

Design and aim of the HYPORT study in regional nodal breast cancer

Design and aim of the HYPORT study in regional nodal breast cancer

Sanjoy Chatterjee • 17 May 2026